Oxford Immunotec Global PLC (NASDAQ:OXFD) has been assigned an average rating of “Hold” from the six brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $19.75.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. BTIG Research set a $21.00 target price on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Robert W. Baird reissued a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, Piper Jaffray Companies decreased their price target on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, October 31st.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the sale, the director now directly owns 17,778 shares in the company, valued at $237,336.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The disclosure for this sale can be found here. 8.11% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its holdings in Oxford Immunotec Global by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after acquiring an additional 1,500 shares during the period. Voya Investment Management LLC lifted its stake in shares of Oxford Immunotec Global by 16.0% in the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after buying an additional 1,845 shares during the period. Rhumbline Advisers lifted its stake in shares of Oxford Immunotec Global by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after buying an additional 2,053 shares during the period. Vanguard Group Inc. lifted its stake in shares of Oxford Immunotec Global by 5.4% in the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock valued at $1,161,000 after buying an additional 3,507 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Oxford Immunotec Global by 6.8% in the second quarter. TIAA CREF Investment Management LLC now owns 76,094 shares of the company’s stock valued at $1,280,000 after buying an additional 4,840 shares during the period. Institutional investors own 89.35% of the company’s stock.

Oxford Immunotec Global (NASDAQ OXFD) opened at $14.59 on Wednesday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a 1 year low of $12.19 and a 1 year high of $19.51.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (OXFD) Receives Average Recommendation of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/06/oxford-immunotec-global-plc-oxfd-receives-average-recommendation-of-hold-from-analysts.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.